Glycomics firm Ezose Biosciences said this week it has inked a collaboration agreement with Merck for biomarker discovery research in diabetes.

The research will focus on identifying changes in glycan patterns in human proteins using Ezose’s GlycanMap platform, the firm said, adding that the work follows on previous collaborations between the two companies.

GlycanMap uses an automated 96-well, bead-based glycan enrichment platform linked to MALDI-TOF mass spectrometry to identify and quantify glycans in biological samples like blood and tissue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.